BYSI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	33 660.00
Average Volume	226 788
Market Cap	83.10M
EPS	$0 ( 2024-04-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.00
ATR14	$0.0210 (0.98%)

Volume Correlation

Long: 0.00 (neutral)

Short: 0.53 (weak)

Signal:(41.828) Neutral

BeyondSpring Inc Correlation

10 Most Positive Correlations
INTZ	0.941
PRAX	0.936
QRTEA	0.932
RUBY	0.923
ALHC	0.922
VVOS	0.922
VERU	0.921
JAGX	0.92
OTRK	0.919
PRCH	0.914

10 Most Negative Correlations
KNBE	-0.922
TIG	-0.912
SNCR	-0.906
SGEN	-0.896
ORTX	-0.889
CCRC	-0.884
XM	-0.879
NEXI	-0.874
CRSA	-0.87
MTCR	-0.869

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BeyondSpring Inc Correlation - Currency/Commodity

-0.75
( moderate negative )

-0.76
( moderate negative )

0.00
( neutral )

-0.61
( weak negative )

-0.14
( neutral )

0.40
( neutral )

BeyondSpring Inc Financials

Annual	2022
Revenue:	$1.35M
Gross Profit:	$1.35M (100.00 %)
EPS:	$-0.930

FY	2022
Revenue:	$1.35M
Gross Profit:	$1.35M (100.00 %)
EPS:	$-0.930

FY	2021
Revenue:	$1.35M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.14

FY	2020
Revenue:	$180 000
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.03

Financial Reports:

No articles found.

BeyondSpring Inc

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.